老年病人血清Aβ42与磷酸化Tau蛋白检测的临床价值

doi:10.3969/j.issn.1003-9198.2022.12.011

实用老年医学 ›› 2022, Vol. 36 ›› Issue (12): 1229-1232.doi: 10.3969/j.issn.1003-9198.2022.12.011

老年病人血清Aβ42与磷酸化Tau蛋白检测的临床价值

郑茜, 陶月, 陈衣强, 刘思远, 陈德柱, 彭鲁, 顾寿永, 蔡敏琪, 柏兵

210008 江苏省南京市,南京大学医学院附属鼓楼医院健康管理中心(郑茜);检验科(陶月);精准医学中心(陈衣强,刘思远,蔡敏琪,柏兵);核医学科(陈德柱);
210029 江苏省南京市,南京医科大学附属脑科医院检验科(彭鲁);
210024 江苏省南京市,江苏省老年病医院(江苏省老年医学研究所)(顾寿永)

收稿日期:2022-01-19 出版日期:2022-12-20 发布日期:2022-11-30
通讯作者: 柏兵,Email: bing.bai@nju.edu.cn
基金资助:
国家自然科学基金面上项目(82172354);江苏省卫健委医学科研面上项目(M2021012);江苏省卫健委老年健康科研课题面上项目(LK2021028);江苏省科技厅社会发展面上项目(BE2018601)

Clinical value of serum amyloid-beta 42 and phosphorylated Tau in elderly patients

ZHENG Qian, TAO Yue, CHEN Yi-qiang, LIU Si-yuan, CHEN De-zhu, PENG Lu, GU Shou-yong, CAI Min-qi, BAI Bing

ZHENG Qian. Health Management Center; TAO Yue. Department of Laboratory Medicine; CHEN Yi-qiang,LIU Si-yuan,CAI Min-qi, BAI Bing. Center for Precision Medicine; CHEN De-zhu. Department of Nuclear Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China;
PENG Lu. Department of Laboratory Medicine, the Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing 210008, China;
GU Shou-yong. Institute of Geriatric Medicine, Jiangsu Province Geriatric Hospital, Nanjing 210024, China

Received:2022-01-19 Online:2022-12-20 Published:2022-11-30

摘要/Abstract

摘要： 目的旨在探讨血清Aβ42与磷酸化Tau蛋白(p-Tau)检测的临床价值。方法收集南京大学医学院附属鼓楼医院已开展的425例门诊或住院60岁以上老年病人的血清Aβ42与p-Tau检测结果(两项均为同时检测),分析其在痴呆或其他疾病病人中的阳性率情况。结果血清Aβ42与p-Tau的总体阳性率分别为36.2%与24.7%, 同时阳性率为21.4%。血清Aβ42在诊断为认知功能障碍、痴呆及AD的病人中的阳性率分别为23.8%、44.9%与50.0%,血清p-Tau分别为12.4%、22.4%与16.7%。然而,它们在具有肺部炎症或感染的病人中阳性率高达64.7%,并且两者几乎同时为阳性。结论血清Aβ42与p-Tau水平对AD的辅助诊断价值可能有限,但对提示肺部感染可能具有临床价值。

关键词: 阿尔茨海默病, 痴呆, 认知功能减退, 血清β淀粉样蛋白, 血清磷酸化Tau蛋白

Abstract: Objective To investigate the clinical value of serum amyloid-beta 42(Aβ42) and phosphorylated Tau (p-Tau). Methods A total of 425 elderly cases were enrolled in this study who received the measurement of Aβ42 and p-Tau at the same time. The positive rate of Aβ42 and p-Tau was analyzed in the elderly patients with dementia or other diseases. Results The overall positive rate of serum Aβ42 and p-Tau was 36.2% and 24.7% respectively, and 21.4% of the patients presented with both positive Aβ42 and p-Tau. Among the patients diagnosed as cognitive impairment, dementia and AD, the positive rate of Aβ42was 23.8%, 44.9%, 50.0% respectively, and the positive rate of p-Tau was 12.4%, 22.4%, 16.7% respectively. However, both of them were positive in 64.7% of the patients with pulmonary infection or inflammation diseases, and they were almost positive simultaneously in a patient. Conclusions The diagnostic values of serum Aβ42 and p-Tau for AD might be limited, but they might be potential indicators of pulmonary infection or inflammation disorders.

Key words: Alzheimer's disease, dementia, cognitive disorder, serum amyloid-beta 42, serum phosphorylated Tau

中图分类号:

R749.16

郑茜, 陶月, 陈衣强, 刘思远, 陈德柱, 彭鲁, 顾寿永, 蔡敏琪, 柏兵. 老年病人血清Aβ42与磷酸化Tau蛋白检测的临床价值[J]. 实用老年医学, 2022, 36(12): 1229-1232.

ZHENG Qian, TAO Yue, CHEN Yi-qiang, LIU Si-yuan, CHEN De-zhu, PENG Lu, GU Shou-yong, CAI Min-qi, BAI Bing. Clinical value of serum amyloid-beta 42 and phosphorylated Tau in elderly patients[J]. Practical Geriatrics, 2022, 36(12): 1229-1232.

参考文献

[1] JACK C R Jr., BENNETT D A, BLENNOW K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease [J]. Alzheimers Dement, 2018, 14(4): 535-562.
[2] LONG J M, HOLTZMAN D M. Alzheimer disease: an update on pathobiology and treatment strategies [J]. Cell, 2019, 179(2): 312-339.
[3] OLSSON B, LAUTNER R, ANDREASSON U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis [J]. Lancet Neurol, 2016, 15(7): 673-684.
[4] 陈心怡,孙杨,徐德恩. 阿尔茨海默病外周血液生物标志物的研究进展 [J]. 实用老年医学, 2021, 35(10): 1076-1079.
[5] 尹倩然,郝敬波,卢海龙,等. 血p-Tau181、Aβ1-42与老年阿尔茨海默病病人认知关系的研究 [J]. 实用老年医学, 2021, 35(6): 741-743.
[6] 黄海华,李明秋,丘江,等. 阿尔茨海默病患者睡眠障碍与血清β-淀粉样蛋白1-42、磷酸化tau蛋白181的相关性研究 [J]. 中华老年医学杂志, 2021, 40(4): 438-443.
[7] MEHTA P D, PIRTTILA T, MEHTA S P, et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease [J]. Arch Neurol, 2000, 57(1): 100-105.
[8] MOTTER R, VIGO-PELFREY C, KHOLODENKO D, et al. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease [J]. Ann Neurol, 1995, 38(4): 643-648.
[9] TEUNISSEN C E, CHIU M J, YANG C C, et al. Plasma amyloid-β (Aβ42) correlates with cerebrospinal fluid Aβ42 in Alzheimer's disease [J]. J Alzheimers Dis, 2018, 62(4): 1857-1863.
[10] LUE L F, SABBAGH M N, CHIU M J, et al. Plasma levels of Aβ42 and Tau identified probable Alzheimer's dementia: Findings in two cohorts [J]. Front Aging Neurosci, 2017, 9: 226.
[11] RISACHER S L, FANDOS N, ROMERO J, et al. Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition [J]. Alzheimers Dement (Amst), 2019, 11: 510-519.
[12] PALMQVIST S, JANELIDZE S, STOMRUD E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status [J]. JAMA Neurol, 2019, 76(9): 1060-1069.
[13] SHI Y, LU X, ZHANG L, et al. Potential value of plasma amyloid-beta, total tau, and neurofilament light for identification of early Alzheimer's disease [J]. ACS Chem Neurosci, 2019, 10(8): 3479-3485.
[14] BAI B, WANG X, LI Y, et al. Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression [J]. Neuron, 2020, 105(4): 700.
[15] KUKULL W A, BRENNER D E, SPECK C E, et al. Causes of death associated with Alzheimer disease: variation by level of cognitive impairment before death [J]. J Am Geriatr Soc, 1994, 42(7): 723-726.
[16] GANGULI M, DODGE H H, SHEN C, et al. Alzheimer disease and mortality: a 15-year epidemiological study [J]. Arch Neurol, 2005, 62(5): 779-784.
[17] WILHELM M, SCHLEGL J, HAHNE H, et al. Mass-spectrometry-based draft of the human proteome [J]. Nature, 2014, 509(7502): 582-587.
[18] KIM M S, PINTO S M, GETNET D, et al. A draft map of the human proteome [J]. Nature, 2014, 509(7502): 575-581.
[19] KINNEY J W, BEMILLER S M, MURTISHAW A S, et al. Inflammation as a central mechanism in Alzheimer's disease [J]. Alzheimers Dement: N Y, 2018, 4: 575-590.
[20] WALKER K A, FICEK B N, WESTBROOK R. Understanding the role of systemic inflammation in Alzheimer's disease [J]. ACS Chem Neurosci, 2019, 10(8): 3340-3342.
[21] WOOD H. Dementia: peripheral inflammation could be a prodromal indicator of dementia [J]. Nat Rev Neurol, 2018, 14(3): 127.
[22] MCMANUS R M, HIGGINS S C, MILLS K H, et al. Respiratory infection promotes T cell infiltration and amyloid-beta deposition in APP/PS1 mice [J]. Neurobiol Aging, 2014, 35(1): 109-121.
[23] LITTLE C S, HAMMOND C J, MACINTYRE A, et al. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice [J]. Neurobiol Aging, 2004, 25(4): 419-429.
[24] EIMER W A, VIJAYA KUMAR D K, NAVALPUR SHANMUGAM N K, et al. Alzheimer's disease-associated beta-amyloid is rapidly seeded by herpesviridae to protect against brain infection [J]. Neuron, 2018, 99(1): 56-63.e3.
[25] KUMAR D K, CHOI S H, WASHICOSKY K J, et al. Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer's disease [J]. Sci Transl Med, 2016, 8(340): 340ra72.
[26] FULOP T, WITKOWSKI J M, BOURGADE K, et al. Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer's disease? [J]. Front Aging Neurosci, 2018, 10: 224.
[27] SY M, KITAZAWA M, MEDEIROS R, et al. Inflammation induced by infection potentiates tau pathological features in transgenic mice [J]. Am J Pathol, 2011, 178(6): 2811-2822.
[28] WOZNIAK M A, FROST A L, ITZHAKI R F. Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1 [J]. J Alzheimers Dis, 2009, 16(2): 341-350.

老年病人血清Aβ42与磷酸化Tau蛋白检测的临床价值

Clinical value of serum amyloid-beta 42 and phosphorylated Tau in elderly patients

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

推荐阅读 10

[1]	包良良, 董靖德. 阻塞性睡眠呼吸暂停与阿尔茨海默病的研究进展[J]. 实用老年医学, 2024, 38(9): 948-952.
[2]	刘乐乐, 解瑞川, 支楠, 高丽. 胶质淋巴系统在阿尔茨海默病中的作用[J]. 实用老年医学, 2024, 38(8): 770-774.
[3]	李清扬, 王婵娟, 王峥. 阿尔茨海默病病人吞咽功能、营养状态与认知功能的相关性研究[J]. 实用老年医学, 2024, 38(6): 577-581.
[4]	刘田, 杨荣礼, 韩慧萍. 血清Aβ1-42、Bcl-2预测老年人认知功能障碍进展为阿尔茨海默病的价值[J]. 实用老年医学, 2024, 38(6): 582-586.
[5]	庞学妍, 李绪领. 高频重复经颅磁刺激治疗阿尔茨海默病的研究进展[J]. 实用老年医学, 2024, 38(6): 634-638.
[6]	张卉, 李霞. 痴呆前心理行为障碍预测阿尔茨海默病的研究进展[J]. 实用老年医学, 2024, 38(5): 512-437.
[7]	高娜, 许梦茹, 张利, 刘玉文, 魏星. 农村老年人运动认知功能减退综合征风险预测模型的构建及验证[J]. 实用老年医学, 2024, 38(4): 353-357.
[8]	王慧娟, 李霞. 主观认知下降转归为阿尔茨海默病的研究现状[J]. 实用老年医学, 2024, 38(4): 414-417.
[9]	王敏, 郭文军, 汤忠泉, 赵晓敏, 欧婷, 李云涛. 听力障碍与阿尔茨海默病相关性的Meta分析[J]. 实用老年医学, 2023, 37(9): 915-919.
[10]	刘丽娟, 江曼, 成勇, 毛高峰, 方煌. 老年脑梗死后血管性痴呆病人血清AGEs、RAGE水平与病情严重程度的关系[J]. 实用老年医学, 2023, 37(8): 853-857.
[11]	马宗娟, 罗昌春, 邓宝凤, 王慧敏, 胡月青. 痴呆病人感染新型冠状病毒后的老年综合评估现状和应对策略[J]. 实用老年医学, 2023, 37(12): 1189-1192.
[12]	郭晓娟, 刘洁, 王瑾, 陆文惠, 高玲, 屈秋民. 西安地区阿尔茨海默病病人药物依从性调查及影响因素分析[J]. 实用老年医学, 2023, 37(1): 47-50.
[13]	王变荣, 郑慧芬, 徐畅, 张荷笛, 黄丹青, 田琦, 陈春苗. 老年人血液中血管紧张素Ⅱ水平与认知功能及内侧颞叶萎缩的相关性研究[J]. 实用老年医学, 2022, 36(7): 684-687.
[14]	杜红娣, 薄琳, 尹荔莎, 骆丹丹, 霍晓鹏. 模拟存在疗法对轻、中度痴呆病人情感淡漠的影响[J]. 实用老年医学, 2022, 36(10): 1071-1074.
[15]	黄馨仪, 韩悦, 翁卫群, 耿桂灵, 顾婷. Rowland通用痴呆评估量表的汉化和信效度检验[J]. 实用老年医学, 2021, 35(7): 668-672.